GERN - Geron Corp Stock Price, Fair Value and News

$4.01+0.03 (+0.75%)

Delayed as of 21 Nov 2024, 09:56 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GERN Price Action

Last 7 days

2.8%

Last 30 days

0.8%

Last 90 days

-11.2%

Trailing 12 Months

107.3%

GERN RSI Chart

GERN Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-11.96

Price/Sales (Trailing)

81.61

Price/Free Cashflow

-11.11

GERN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GERN Fundamentals

GERN Revenue

Revenue (TTM)

29.5M

Rev. Growth (Yr)

17.1K%

Rev. Growth (Qtr)

3.1K%

GERN Earnings

Earnings (TTM)

-201.2M

Earnings Growth (Yr)

40.97%

Earnings Growth (Qtr)

60.75%

GERN Profitability

Return on Equity

-68.83%

Return on Assets

-45.22%

Free Cashflow Yield

-9%

GERN Investor Care

Shares Dilution (1Y)

11.31%

Diluted EPS (TTM)

-0.31

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	520.0K	1.4M	29.5M	0
2023	494.0K	450.0K	317.0K	237.0K
2022	1.4M	1.3M	1.5M	596.0K
2021	338.0K	402.0K	403.0K	1.4M
2020	1.5M	397.0K	374.0K	253.0K
2019	3.3M	3.7M	2.8M	2.6M
2018	922.0K	1.5M	2.4M	2.5M
2017	6.0M	5.9M	968.0K	1.1M
2016	28.8M	21.3M	13.7M	6.2M
2015	1.2M	1.1M	36.3M	36.4M
2014	992.0K	1.2M	1.2M	1.2M
2013	2.2M	2.2M	1.7M	1.3M
2012	2.2M	1.9M	2.3M	2.7M
2011	4.2M	3.6M	3.3M	2.4M
2010	0	2.3M	3.0M	3.6M
2009	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

CEO	Dr. John A. Scarlett M.D.
WEBSITE	geron.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	107

Geron Corp Frequently Asked Questions

What is the ticker symbol for Geron Corp? What does GERN stand for in stocks?

GERN is the stock ticker symbol of Geron Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Geron Corp (GERN)?

As of Wed Nov 20 2024, market cap of Geron Corp is 2.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GERN stock?

You can check GERN's fair value in chart for subscribers.

Is Geron Corp a good stock to buy?

The fair value guage provides a quick view whether GERN is over valued or under valued. Whether Geron Corp is cheap or expensive depends on the assumptions which impact Geron Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GERN.

What is Geron Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, GERN's PE ratio (Price to Earnings) is -11.96 and Price to Sales (PS) ratio is 81.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GERN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Geron Corp's stock?

In the past 10 years, Geron Corp has provided 0.007 (multiply by 100 for percentage) rate of return.